US20050085495A1 - Process for preparing amino crotonyl compounds - Google Patents
Process for preparing amino crotonyl compounds Download PDFInfo
- Publication number
- US20050085495A1 US20050085495A1 US10/941,116 US94111604A US2005085495A1 US 20050085495 A1 US20050085495 A1 US 20050085495A1 US 94111604 A US94111604 A US 94111604A US 2005085495 A1 US2005085495 A1 US 2005085495A1
- Authority
- US
- United States
- Prior art keywords
- amino
- chloro
- tetrahydrofuran
- yloxy
- fluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CP(C)(=O)CC(=O)NC1=CC2=C(N[RaH])C=CN=C2C=C1O[C@H]1CCOC1.I[V]I.[3*]N([4*])C/C=C/C(=O)NC1=CC2=C(N[RaH])C=CN=C2C=C1O[C@H]1CCOC1.[V]I Chemical compound CP(C)(=O)CC(=O)NC1=CC2=C(N[RaH])C=CN=C2C=C1O[C@H]1CCOC1.I[V]I.[3*]N([4*])C/C=C/C(=O)NC1=CC2=C(N[RaH])C=CN=C2C=C1O[C@H]1CCOC1.[V]I 0.000 description 4
- PRSSKFUAQPOPHC-UHFFFAOYSA-K C.C.C.CC1=C([N+](=O)[O-])C2=NC=NC(O)=C2C=C1.CC1=CC(N)=C(C(=O)O)C=C1.CC1=CC2=NC=NC(O)=C2C=C1.CC1=CC2=NC=NC(O)=C2C=C1[N+](=O)[O-].I[V](I)I Chemical compound C.C.C.CC1=C([N+](=O)[O-])C2=NC=NC(O)=C2C=C1.CC1=CC(N)=C(C(=O)O)C=C1.CC1=CC2=NC=NC(O)=C2C=C1.CC1=CC2=NC=NC(O)=C2C=C1[N+](=O)[O-].I[V](I)I PRSSKFUAQPOPHC-UHFFFAOYSA-K 0.000 description 1
- VOFQFFJULUFDLB-SYWGCQIGSA-N C.CN(C)C/C=C/C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OC1CCOC1.CN(C)C/C=C/C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OC1CCOC1.I.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O Chemical compound C.CN(C)C/C=C/C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OC1CCOC1.CN(C)C/C=C/C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OC1CCOC1.I.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O VOFQFFJULUFDLB-SYWGCQIGSA-N 0.000 description 1
- IVHIIFDUISUSAS-KVZPWHKUSA-L CC1=C(N)C=C2C(=C1)N=CN=C2N[RaH].CC1=C(NC(=O)/C=C/C[Rb])C=C2C(=C1)N=CN=C2N[RaH].II.I[IH]I.O=C(Br)/C=C/C[Rb].[V]I Chemical compound CC1=C(N)C=C2C(=C1)N=CN=C2N[RaH].CC1=C(NC(=O)/C=C/C[Rb])C=C2C(=C1)N=CN=C2N[RaH].II.I[IH]I.O=C(Br)/C=C/C[Rb].[V]I IVHIIFDUISUSAS-KVZPWHKUSA-L 0.000 description 1
- SHVYBVGUWIKFNO-CTNBMEOLSA-N CC1=CC2=NC=CC(N[RaH])=C2C=C1[N+](=O)[O-].NC1=CC2=C(N[RaH])C=CN=C2C=C1O[C@H]1CCOC1.O=[N+]([O-])C1=CC2=C(N[RaH])C=CN=C2C=C1O[C@H]1CCOC1.[V] Chemical compound CC1=CC2=NC=CC(N[RaH])=C2C=C1[N+](=O)[O-].NC1=CC2=C(N[RaH])C=CN=C2C=C1O[C@H]1CCOC1.O=[N+]([O-])C1=CC2=C(N[RaH])C=CN=C2C=C1O[C@H]1CCOC1.[V] SHVYBVGUWIKFNO-CTNBMEOLSA-N 0.000 description 1
- ADAYCYGJNUFHSM-UHFFFAOYSA-N CC1=CC2=NC=NC(Cl)=C2C=C1[N+](=O)[O-].CC1=CC2=NC=NC(N[RaH])=C2C=C1[N+](=O)[O-].CC1=CC2=NC=NC(O)=C2C=C1[N+](=O)[O-] Chemical compound CC1=CC2=NC=NC(Cl)=C2C=C1[N+](=O)[O-].CC1=CC2=NC=NC(N[RaH])=C2C=C1[N+](=O)[O-].CC1=CC2=NC=NC(O)=C2C=C1[N+](=O)[O-] ADAYCYGJNUFHSM-UHFFFAOYSA-N 0.000 description 1
- KHFGKGIOMJCXFO-BJILWQEISA-N CCOP(=O)(CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OC1CCOC1)OCC.CN(C)C/C=C/C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OC1CCOC1 Chemical compound CCOP(=O)(CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OC1CCOC1)OCC.CN(C)C/C=C/C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OC1CCOC1 KHFGKGIOMJCXFO-BJILWQEISA-N 0.000 description 1
- CSNCUJYZJIQPIL-WUSPCOQVSA-N CCOP(=O)(CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OC1CCOC1)OCC.NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@H]1CCOC1 Chemical compound CCOP(=O)(CC(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OC1CCOC1)OCC.NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@H]1CCOC1 CSNCUJYZJIQPIL-WUSPCOQVSA-N 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N CN(C)C/C=C/C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@H]1CCOC1 Chemical compound CN(C)C/C=C/C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@H]1CCOC1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- RLJUDPOLSVDUAY-IDMXKUIJSA-M CP(C)(=O)CC(=O)NC1=CC2=C(N[RaH])C=CN=C2C=C1O[C@H]1CCOC1 Chemical compound CP(C)(=O)CC(=O)NC1=CC2=C(N[RaH])C=CN=C2C=C1O[C@H]1CCOC1 RLJUDPOLSVDUAY-IDMXKUIJSA-M 0.000 description 1
- FWKOWOCEERGOBT-QYMNPJHNSA-L CP(C)(=O)CC(=O)NC1=CC2=C(N[RaH])C=CN=C2C=C1O[C@H]1CCOC1.NC1=CC2=C(N[RaH])C=CN=C2C=C1O[C@H]1CCOC1.[V].[V]I Chemical compound CP(C)(=O)CC(=O)NC1=CC2=C(N[RaH])C=CN=C2C=C1O[C@H]1CCOC1.NC1=CC2=C(N[RaH])C=CN=C2C=C1O[C@H]1CCOC1.[V].[V]I FWKOWOCEERGOBT-QYMNPJHNSA-L 0.000 description 1
- AUKUMNGQDLEFMJ-UHFFFAOYSA-N NC1=CC(OC2CCOC2)=C([N+](=O)[O-])C=C1.O=[N+]([O-])C1=C(O)C=C(F)C=C1.O=[N+]([O-])C1=C(OC2CCOC2)C=C(F)C=C1.O=[N+]([O-])C1=CC2=C(N[RaH])C=CN=C2C=C1OC1CCOC1.O=[N+]([O-])C1=CC2=C(O)C=CN=C2C=C1OC1CCOC1 Chemical compound NC1=CC(OC2CCOC2)=C([N+](=O)[O-])C=C1.O=[N+]([O-])C1=C(O)C=C(F)C=C1.O=[N+]([O-])C1=C(OC2CCOC2)C=C(F)C=C1.O=[N+]([O-])C1=CC2=C(N[RaH])C=CN=C2C=C1OC1CCOC1.O=[N+]([O-])C1=CC2=C(O)C=CN=C2C=C1OC1CCOC1 AUKUMNGQDLEFMJ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates to an improved process for preparing aminocrotonyl compounds such as for example 4-[(3-chloro-4-fluorophenyl)amino]-6- ⁇ [4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino ⁇ -7-((S)-tetrahydrofuran-3-yloxy)-quinazoline and the physiologically acceptable salts thereof, particularly 4-[(3-chloro-4-fluorophenyl)amino]-6- ⁇ [4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino ⁇ -7-((S)-tetrahydrofuran-3-yloxy)-quinazoline dimaleate, as well as 4-[(3-chloro-4-fluorophenyl)amino]-6- ⁇ [4-(N,N-dimethylamino)-1-oxo-2-buten-1-y
- 4-[(3-chloro-4-fluorophenyl)amino]-6- ⁇ [4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]-amino ⁇ -7-((S)-tetrahydrofuran-3-yloxy)-quinazoline has the following structure: and is already known from WO 02/50043, which describes compounds with valuable pharmacological properties, including in particular an inhibiting effect on signal transduction mediated by tyrosinekinases and an inhibitory effect on signal transduction mediated by the Epidermal Growth Factor receptor (EGF-R). Therefore, compounds of this type are suitable for the treatment of diseases, particularly for the treatment of tumoral diseases, diseases of the lungs and respiratory tract and diseases of the gastrointestinal tract and bile duct and gall bladder.
- EGF-R Epidermal Growth Factor receptor
- WO 02/50043 discloses a method of preparation wherein aminocrotonyl compounds (IV) such as for example 4-[(3-chloro4-fluorophenyl)amino]-6- ⁇ [4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino ⁇ -7-((S)-tetrahydrofuran-3-yloxy)-quinazoline are prepared in a one-pot reaction from the corresponding aniline component (II), bromocrotonic acid (Ill), oxalyl chloride and a secondary amine (see Diagram 1).
- Diagram 1 Diagram 1:
- the aim of the present invention is to provide a process which allows the production of aminocrotonylarylamides, particularly 4-[(3-chloro-4-fluorophenyl)amino]-6- ⁇ [4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino ⁇ -7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, using highly pure starting materials which are readily available and without any great technical expenditure.
- This new process should therefore also be suitable for synthesis on an industrial scale and hence for commercial application.
- the corresponding aminoaryl compound (V) is reacted with a di-(C 1-4 -alkyl)-phosphonoacetic acid, preferably with diethylphos-phonoacetic acid, in suitable solvents, after corresponding activation, preferably with 1,1 -carbonyldiimidazole, 1,1 -carbonylditriazole or propanephosphonic anhydride, particularly preferably with 1,1-carbonyldiimidazole, according to Diagram 2.
- the solvent used may be for example tetrahydrofuran (THF), dimethylformamide (DMF) or ethyl acetate.
- the activation may be carried out by any possible method of amide linking, i.e. for example with 1,1-carbonyidiimidazole, 1,1-carbonylditriazole, DCC (N,N-dicyclohexylcarbodiimide), EDC (N′-(dimethylaminopropyl)-N-ethylcarbodiimide), TBTU O-(benzotriazol-1-yl)-N,N,N′, N′-tetramethyluronium tetrafluoroborate, thiazolidine-2-thione or by conversion into the corresponding acid chloride, possibly using thionyl chloride.
- 1,1-carbonyidiimidazole 1,1-carbonylditriazole
- DCC N,N-dicyclohexylcarbodiimide
- EDC N′-(dimethylaminopropyl)-N-ethylcarbodiimide
- TBTU O-
- the activation may be carried out using organic bases such as triethylamine or pyridine, while DMAP (dimethylaminopyridine) may additionally be added.
- Suitable solvents include DMF, THF, ethyl acetate, toluene, chlorinated hydrocarbons or mixtures thereof.
- the arylamide (VI) thus obtained in a high yield and high purity is reacted with the corresponding 2-aminoacetaldehyde using suitable organic or inorganic bases in the sense of a Wittig-Horner-Emmons reaction (Diagram 3).
- This reaction may be carried out directly or after isolation of the compound (VI), for example by precipitation by the addition of tert-butylmethyl ether, for example.
- Suitable bases include for example DBU (1,5-diazabicyclo[4.3.0]non-5-ene), sodium hydroxide and potassium hydroxide, of which sodium hydroxide and potassium hydroxide are preferred and potassium hydroxide is particularly preferred.
- a corresponding equivalent e.g. a hydrate or acetal, may be used, from which the aldehyde is released (beforehand or in situ).
- the acetals used may be for example compounds of the following general type: wherein R 2 to R 5 in each case represent a straight-chain or branched C 1-4 -alkyl group, while the groups may be identical or different.
- aminocrotonylarylamide of formula (VII) for example 4-[(3-chloro-4-fluorophenyl)amino]-6- ⁇ [4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino ⁇ -7-((S)-tetrahydrofuran-3-yloxy)-quinazoline of formula (I), may then be converted into the salts thereof, particularly the physiologically acceptable salts thereof, by methods known per se. Preferably they are converted into fumarates, tartrates or maleates.
- the compound (I) is dissolved in a suitable solvent, such as for example methanol, isopropanol, n-butanol or ethanol, optionally with the addition of water, preferably ethanol, and combined with crystalline maleic acid or a maleic acid solution, with heating.
- a suitable solvent such as for example methanol, isopropanol, n-butanol or ethanol
- water preferably ethanol
- crystalline maleic acid or a maleic acid solution with heating.
- ethanol ethanol
- the reaction conditions are preferably selected so that the desired salt crystallises out as quickly as possible.
- Preferably approx. 2 equivalents of maleic acid are used.
- the starting compound of formula (V) may for example be prepared as follows in accordance with methods known from the literature.
- the invention also relates to 4-[(3-chloro-4-fluorophenyl)amino]-6- ⁇ [4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino ⁇ -7-((S)-tetrahydrofuran-3-yloxy)-quinazoline dimaleate.
- This salt is particularly suitable for pharmaceutical use as it exists in only one crystalline modification, which is moreover anhydrous and very stable.
- an active substance not only has to exhibit the desired activity, but must also conform to additional requirements in order to be allowed to be used as a pharmaceutical composition. These parameters are to a large extent connected with the physicochemical nature of the active substance.
- examples of these parameters are the stability of effect of the starting material under various environmental conditions, stability during production of the pharmaceutical formulation and stability in the final medicament compositions.
- the pharmaceutically active substance used for preparing the pharmaceutical compositions should therefore have a high stability which must be guaranteed even under various environmental conditions. This is absolutely essential to prevent the use of pharmaceutical compositions which contain, in addition to the actual active substance, breakdown products thereof, for example. In such cases the content of active substance in pharmaceutical formulations might be less than that specified.
- the absorption of moisture reduces the content of pharmaceutically active substance on account of the weight gain caused by the uptake of water.
- Pharmaceutical compositions with a tendency to absorb moisture have to be protected from damp during storage, e.g. by the addition of suitable drying agents or by storing the medicament in a damp-proof environment.
- the uptake of moisture can reduce the content of pharmaceutically active substance during manufacture if the medicament is exposed to the environment without being protected from damp in any way.
- a pharmaceutically active substance should therefore have only limited hygroscopicity.
- the solubility of the active substance Another criterion which may be of exceptional importance under certain circumstances depending on the choice of formulation or the choice of manufacturing process is the solubility of the active substance. If for example pharmaceutical solutions are prepared (e.g. for infusions) it is essential that the active substance should be sufficiently soluble in physiologically acceptable solvents. It is also very important for drugs which are to be taken orally that the active substance should be sufficiently soluble.
- the problem of the present invention is to provide a pharmaceutically active substance which not only is characterised by high pharmacological potency but also satisfies the above-mentioned physicochemical requirements as far as possible.
- 4-[(3-chloro-4-fluorophenyl)amino]-6- ⁇ [4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]-amino ⁇ -7-((S)-tetrahydrofuran-3-yloxy)-quinazoline dimaleate has a melting point of 178° C. (cf. the thermoanalysis shown in FIG. 2 ).
- solution A 58 kg of 1,1-carbonyldiimidazole (22.16 mol) are placed in 12.8 litres of tetrahydrofuran and at 40° C. combined with 4.52 kg (22.16 mol) of diethylphosphonoacetic acid dissolved in 6.5 litres of tetrahydrofuran. The mixture is stirred for 30 minutes at 40° C. The resulting solution is referred to as solution A.
- solution B 5.6 litres of 30% hydrochloric acid (53.17 mol) are added to 4.4 litres of water. Then 4.28 kg of 95% (dimethylamino)-acetaldehyde-diethylacetal (26.59 mol) are added dropwise within 20 minutes at 30° C. The reaction solution is stirred for 8 hours at 35° C. stirred, cooled to 5° C. and stored under argon. This solution is referred to as solution B.
- solution C 4.55 kg (68.06 mol) of potassium hydroxide are dissolved in 23.5 litres of water and cooled to ⁇ 5° C. This solution is referred to as solution C.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/941,116 US20050085495A1 (en) | 2003-10-17 | 2004-09-15 | Process for preparing amino crotonyl compounds |
US11/457,622 US8426586B2 (en) | 2003-10-17 | 2006-07-14 | Process for preparing amino crotonyl compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10349113A DE10349113A1 (de) | 2003-10-17 | 2003-10-17 | Verfahren zur Herstellung von Aminocrotonylverbindungen |
DE10349113 | 2003-10-17 | ||
US51777703P | 2003-11-06 | 2003-11-06 | |
US10/941,116 US20050085495A1 (en) | 2003-10-17 | 2004-09-15 | Process for preparing amino crotonyl compounds |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/457,622 Continuation US8426586B2 (en) | 2003-10-17 | 2006-07-14 | Process for preparing amino crotonyl compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050085495A1 true US20050085495A1 (en) | 2005-04-21 |
Family
ID=34428508
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/941,116 Abandoned US20050085495A1 (en) | 2003-10-17 | 2004-09-15 | Process for preparing amino crotonyl compounds |
US11/457,622 Active 2029-10-10 US8426586B2 (en) | 2003-10-17 | 2006-07-14 | Process for preparing amino crotonyl compounds |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/457,622 Active 2029-10-10 US8426586B2 (en) | 2003-10-17 | 2006-07-14 | Process for preparing amino crotonyl compounds |
Country Status (35)
Country | Link |
---|---|
US (2) | US20050085495A1 (pl) |
EP (2) | EP1678165B1 (pl) |
JP (2) | JP4594317B2 (pl) |
KR (2) | KR101282812B1 (pl) |
CN (2) | CN1867564B (pl) |
AR (1) | AR046118A1 (pl) |
AU (2) | AU2004281938B2 (pl) |
BR (2) | BR122013033343B8 (pl) |
CA (2) | CA2759063C (pl) |
CY (2) | CY1114866T1 (pl) |
DE (1) | DE10349113A1 (pl) |
DK (2) | DK2508521T4 (pl) |
EA (1) | EA016624B1 (pl) |
EC (1) | ECSP066509A (pl) |
ES (2) | ES2440466T3 (pl) |
HK (1) | HK1095817A1 (pl) |
HR (2) | HRP20160246T4 (pl) |
HU (1) | HUE028254T2 (pl) |
IL (2) | IL174951A (pl) |
ME (1) | ME00341B (pl) |
MX (2) | MX338920B (pl) |
MY (2) | MY149921A (pl) |
NO (2) | NO333971B1 (pl) |
NZ (2) | NZ583049A (pl) |
PE (2) | PE20100267A1 (pl) |
PL (2) | PL2508521T5 (pl) |
PT (2) | PT1678165E (pl) |
RS (3) | RS53398B (pl) |
SG (1) | SG139743A1 (pl) |
SI (2) | SI2508521T2 (pl) |
TW (2) | TWI348468B (pl) |
UA (2) | UA91401C2 (pl) |
UY (2) | UY28559A1 (pl) |
WO (1) | WO2005037824A2 (pl) |
ZA (1) | ZA200602234B (pl) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020173509A1 (en) * | 2000-12-20 | 2002-11-21 | Frank Himmelsbach | Quinazoline derivatives and phamaceutical compositions containing them |
US20070027170A1 (en) * | 2003-10-17 | 2007-02-01 | Rainer Soyka | Process for preparing amino crotonyl compounds |
EP1951686A1 (en) * | 2005-11-08 | 2008-08-06 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof |
US20080254040A1 (en) * | 2003-04-29 | 2008-10-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
US20090306378A1 (en) * | 2006-01-26 | 2009-12-10 | Juergen Schroeder | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
US20090306044A1 (en) * | 2005-11-11 | 2009-12-10 | Flavio Solca | Quinazoline derivatives for the treatment of cancer diseases |
US20090306101A1 (en) * | 2005-11-11 | 2009-12-10 | Flavio Solca | Combination treatment of cancer comprising egfr/her2 inhibitors |
US20090318480A1 (en) * | 2006-09-18 | 2009-12-24 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring egfr mutations |
US20100069414A1 (en) * | 1999-06-21 | 2010-03-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US20100144639A1 (en) * | 2002-05-11 | 2010-06-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the egfr-mediated signal transduction for the treatment of benign prostatic hyperplasia (bph) / prostatic hypertrophy |
WO2010104406A1 (en) | 2009-03-11 | 2010-09-16 | Auckland Uniservices Limited | Prodrug forms of kinase inhibitors and their use in therapy |
WO2011003853A2 (en) | 2009-07-06 | 2011-01-13 | Boehringer Ingelheim International Gmbh | Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
US20110142929A1 (en) * | 2008-06-06 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Solid pharmaceutical formulations comprising bibw 2992 |
US20120107304A1 (en) * | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
WO2013052157A1 (en) | 2011-10-06 | 2013-04-11 | Ratiopharm Gmbh | Crystalline forms of afatinib di-maleate |
US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
WO2016051380A1 (en) * | 2014-10-01 | 2016-04-07 | Sun Pharmaceutical Industries Limited | Crystalline form of afatinib dimaleate |
US9309228B2 (en) | 2012-07-19 | 2016-04-12 | Boehringer Ingelheim International Gmbh | Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as a medicament and the preparation thereof |
US20160122329A1 (en) * | 2014-01-02 | 2016-05-05 | IVAX International GmbH | Crystalline forms of afatinib di-maleate |
US20160207907A1 (en) * | 2015-01-15 | 2016-07-21 | Hangzhou Pushai Pharmaceutical Technology Co., Ltd. | Crystalline Forms of Afatinib Monomaleate, Preparation Methods and Pharmaceutical Compositions Thereof |
WO2016199076A3 (en) * | 2015-06-12 | 2017-03-09 | Fresenius Kabi Oncology Ltd. | Polymorphic forms of afatinib free base and afatinib dimaleate |
US9725439B2 (en) | 2013-09-28 | 2017-08-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinazoline derivative and preparation method therefor |
US10231973B2 (en) | 2015-03-20 | 2019-03-19 | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. | Salts of quinazoline derivative and method for preparing the same |
US10525059B2 (en) | 2015-08-21 | 2020-01-07 | Fresenius Kabi Oncology, Ltd. | Pharmaceutical compositions comprising Afatinib |
US11136314B2 (en) | 2017-04-06 | 2021-10-05 | Johnson Matthey Public Limited Company | Forms of afatinib dimaleate |
US11446302B2 (en) | 2016-11-17 | 2022-09-20 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010081817A1 (en) | 2009-01-14 | 2010-07-22 | Boehringer Ingelheim International Gmbh | Method for treating colorectal cancer |
JP2012526766A (ja) | 2009-05-14 | 2012-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 腫瘍性及び線維性疾患の処置における新規な併用療法 |
WO2011002523A1 (en) | 2009-07-02 | 2011-01-06 | Kanionusa Inc. | Phosphorus containing quinazoline compounds and methods of use |
EP2509592A1 (en) | 2009-12-07 | 2012-10-17 | Boehringer Ingelheim International GmbH | Bibw 2992 for use in the treatment of triple negative breast cancer |
WO2012027445A1 (en) | 2010-08-26 | 2012-03-01 | Boehringer Ingelheim International Gmbh | Methods of administering an egfr inhibitor |
JP5808818B2 (ja) * | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
BR112013022552B1 (pt) | 2011-03-04 | 2021-11-23 | Newgen Therapeutics, Inc | Compostos de quinazolina substituídos com alcino, seu uso, composição farmacêutica, e kit |
CN102731485B (zh) * | 2011-04-02 | 2016-06-15 | 齐鲁制药有限公司 | 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途 |
CN102918029B (zh) * | 2011-05-17 | 2015-06-17 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
CN102838590B (zh) * | 2011-06-21 | 2014-07-09 | 苏州迈泰生物技术有限公司 | 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途 |
US20170079444A1 (en) * | 2011-09-22 | 2017-03-23 | Future Foam, Inc. | Enhanced washable mattress topper |
CN103073539B (zh) * | 2011-10-26 | 2016-05-11 | 齐鲁制药有限公司 | 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途 |
US20150368230A1 (en) | 2013-02-01 | 2015-12-24 | Boehringer Ingelheim International Gmbh | Radiolabeled quinazoline derivatives |
CN103254156B (zh) * | 2013-05-10 | 2015-08-26 | 苏州明锐医药科技有限公司 | 阿法替尼中间体的制备方法 |
WO2014180271A1 (zh) * | 2013-05-10 | 2014-11-13 | 苏州明锐医药科技有限公司 | 阿法替尼及其中间体的制备方法 |
CN103242303B (zh) * | 2013-05-16 | 2015-03-25 | 苏州明锐医药科技有限公司 | 阿法替尼的制备方法 |
CN103288808B (zh) * | 2013-05-16 | 2015-11-11 | 苏州明锐医药科技有限公司 | 一种阿法替尼的制备方法 |
CN106279126B (zh) * | 2013-07-16 | 2019-05-24 | 杭州普晒医药科技有限公司 | 阿法替尼酸加成盐及其晶型、其制备方法及药物组合物 |
CN104710413B (zh) * | 2013-12-16 | 2019-05-03 | 江苏豪森药业集团有限公司 | 二马来酸阿法替尼的制备方法 |
CN104744445A (zh) * | 2013-12-30 | 2015-07-01 | 广东东阳光药业有限公司 | 一种酪氨酸激酶抑制剂的晶型 |
CN104803992A (zh) * | 2014-01-25 | 2015-07-29 | 广东东阳光药业有限公司 | 阿法替尼盐的晶型 |
WO2016001844A1 (en) * | 2014-06-30 | 2016-01-07 | Sun Pharmaceutical Industries Limited | Amorphous form of afatinib dimaleate |
CN105315263B (zh) * | 2014-07-30 | 2018-11-27 | 正大天晴药业集团股份有限公司 | 阿法替尼中间体的合成方法 |
WO2016027243A1 (en) * | 2014-08-21 | 2016-02-25 | Dr. Reddy’S Laboratories Limited | Novel solid state forms of afatinib dimaleate |
CN105534920B (zh) * | 2014-10-29 | 2020-07-10 | 江苏豪森药业集团有限公司 | 一种药物组合物及其制备方法 |
CN104402872B (zh) * | 2014-11-14 | 2016-08-24 | 广东东阳光药业有限公司 | 一种结晶除杂方法 |
CN104447713B (zh) * | 2014-11-18 | 2019-03-29 | 江苏奥赛康药业股份有限公司 | 阿法替尼化合物的制备方法 |
EP3023421A1 (en) * | 2014-11-21 | 2016-05-25 | Sandoz Ag | Crystalline forms of afatinib dimaleate |
CN104529800B (zh) * | 2014-12-08 | 2017-01-25 | 重庆威鹏药业有限公司 | 反式‑4‑二甲基氨基巴豆酸及盐的制备方法 |
CN105801567A (zh) * | 2014-12-31 | 2016-07-27 | 徐州万邦金桥制药有限公司 | 一种双马来酸阿法替尼的纯化方法 |
CA2982423C (en) * | 2015-04-17 | 2024-01-16 | Hetero Labs Ltd | Polymorphs and process for the preparation of quinazolinyl derivatives |
CN105859641B (zh) * | 2015-05-05 | 2018-11-16 | 杭州华东医药集团新药研究院有限公司 | 喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途 |
CN104892584B (zh) * | 2015-05-27 | 2018-03-23 | 重庆泰濠制药有限公司 | 一种阿法替尼双马来酸盐无定型态及其制备方法、制剂 |
CN104926800A (zh) * | 2015-06-26 | 2015-09-23 | 河北神威药业有限公司 | 一种阿法替尼二马来酸盐的结晶形式及其制备方法 |
CN105175331B (zh) * | 2015-08-14 | 2019-04-26 | 江苏苏中药业集团股份有限公司 | 一种egfr类分子靶向抗肿瘤药物的制备方法 |
WO2017093789A1 (en) * | 2015-12-03 | 2017-06-08 | Mylan Laboratories Ltd. | Polymorphic forms of afatinib dimaleate |
CN106831733B (zh) * | 2015-12-07 | 2021-05-11 | 海南先声药业有限公司 | 阿法替尼顺式异构体的制备方法与应用 |
CN106866641A (zh) * | 2015-12-11 | 2017-06-20 | 河北神威药业有限公司 | 一种阿法替尼的精制方法 |
CN108430990B (zh) | 2015-12-25 | 2020-08-25 | 山东轩竹医药科技有限公司 | 喹唑啉衍生物的晶体及其制备方法 |
CN106916147A (zh) * | 2015-12-25 | 2017-07-04 | 中美华世通生物医药科技(武汉)有限公司 | 化合物及其制备方法和用途 |
CN105669658B (zh) * | 2016-04-05 | 2018-06-29 | 北京民康百草医药科技有限公司 | 一种阿法替尼的精制方法 |
CN107488171B (zh) * | 2016-06-10 | 2020-08-28 | 山东新时代药业有限公司 | 一种阿法替尼制备方法 |
CN107488194B (zh) * | 2016-06-10 | 2021-07-30 | 山东新时代药业有限公司 | 一种阿法替尼中间体及其制备方法 |
CN107488153B (zh) * | 2016-06-10 | 2020-06-23 | 山东新时代药业有限公司 | 一种阿法替尼中间体化合物 |
CN107488172B (zh) * | 2016-06-10 | 2020-06-12 | 山东新时代药业有限公司 | 一种阿法替尼的制备方法 |
CN106243092B (zh) * | 2016-07-28 | 2019-02-15 | 南京臣功制药股份有限公司 | 一种高选择性制备马来酸阿法替尼的方法 |
TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
CN108358900A (zh) * | 2018-03-30 | 2018-08-03 | 东北制药集团股份有限公司 | 一种阿法替尼及其马来酸盐的制备方法 |
KR20190141607A (ko) | 2018-06-14 | 2019-12-24 | 주식회사 에이티파머 | 알로페론을 포함하는 췌장암 치료용 조성물 및 치료 보조제 |
KR102257913B1 (ko) | 2018-07-17 | 2021-05-28 | 주식회사 에이티파머 | 알로페론을 포함하는 폐섬유증 치료용 조성물 |
CN109824657A (zh) * | 2019-03-26 | 2019-05-31 | 石药集团中奇制药技术(石家庄)有限公司 | 一种二马来酸阿法替尼新晶型及其制备方法和应用 |
CN110563710B (zh) * | 2019-09-21 | 2020-05-19 | 广东安诺药业股份有限公司 | 一种马来酸阿法替尼的制备方法 |
CN110590754A (zh) * | 2019-09-21 | 2019-12-20 | 广东安诺药业股份有限公司 | 一种马来酸阿法替尼中间体的制备方法 |
CN113121512B (zh) * | 2019-12-30 | 2022-11-04 | 江苏晶立信医药科技有限公司 | 一种喹唑啉基丁烯酰胺类化合物的制备方法 |
KR20210106158A (ko) | 2020-02-20 | 2021-08-30 | 서울대학교산학협력단 | 알로페론을 포함하는 항암 치료 보조제 |
KR20210106157A (ko) | 2020-02-20 | 2021-08-30 | 서울대학교산학협력단 | 알로페론을 포함하는 난소암 치료용 조성물 및 치료 보조제 |
CN114315808A (zh) * | 2020-10-10 | 2022-04-12 | 西安新通药物研究有限公司 | 一种高收率马来酸阿法替尼的制备方法 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8618846D0 (en) | 1986-08-01 | 1986-09-10 | Smithkline Beckman Corp | Chemical process |
JPS6442472A (en) | 1987-08-10 | 1989-02-14 | Kanebo Ltd | Quinazoline derivative, production thereof and brain function disorder improving agent containing said derivative as active ingredient |
GB9005014D0 (en) * | 1990-03-06 | 1990-05-02 | Janssen Pharmaceutica Nv | N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives |
RU2043352C1 (ru) * | 1991-07-01 | 1995-09-10 | Пермский фармацевтический институт | 2-пропил-3- (5-нитрофурфулиден)амино- 4(3н)-хиназолинон, проявляющий противостафилококковую и анальгетическую активность |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
DK0817775T3 (da) | 1995-03-30 | 2001-11-19 | Pfizer | Quinazolinderivater |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
JP4146514B2 (ja) | 1995-07-06 | 2008-09-10 | ノバルティス アクチエンゲゼルシャフト | ピロロピリミジン類およびその製造方法 |
SI0892789T2 (sl) | 1996-04-12 | 2010-03-31 | Warner Lambert Co | Ireverzibilni inhibitorji tirozin kinaz |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
US6262088B1 (en) | 1998-11-19 | 2001-07-17 | Berlex Laboratories, Inc. | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
DE19911366A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
ID29800A (id) * | 1999-02-27 | 2001-10-11 | Boehringer Ingelheim Pharma | Turunan-turunan 4-amino-kinazolin dan kinolin yang mempunyai efek inhibitor pada transduksi signal yang dimediasi oleh tirosin kinase |
DE19911509A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
CA2375259C (en) | 1999-06-21 | 2009-04-28 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US6627634B2 (en) | 2000-04-08 | 2003-09-30 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
US20030158196A1 (en) | 2002-02-16 | 2003-08-21 | Boehringer Ingelheim Pharma Gmbh Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
DE10063435A1 (de) * | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
DE10204462A1 (de) * | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
DE10221018A1 (de) | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
US20030225079A1 (en) | 2002-05-11 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
PE20040945A1 (es) | 2003-02-05 | 2004-12-14 | Warner Lambert Co | Preparacion de quinazolinas substituidas |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US8404697B2 (en) | 2005-11-11 | 2013-03-26 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
US20090306101A1 (en) | 2005-11-11 | 2009-12-10 | Flavio Solca | Combination treatment of cancer comprising egfr/her2 inhibitors |
CA2639936C (en) | 2006-01-26 | 2014-06-17 | Boehringer Ingelheim International Gmbh | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
RU2492864C2 (ru) | 2006-09-18 | 2013-09-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ лечения рака, несущего мутации egfr |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
PE20100252A1 (es) | 2008-06-06 | 2010-04-12 | Boehringer Ingelheim Int | Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina |
WO2010081817A1 (en) | 2009-01-14 | 2010-07-22 | Boehringer Ingelheim International Gmbh | Method for treating colorectal cancer |
US9545381B2 (en) | 2009-07-06 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
EP2509592A1 (en) | 2009-12-07 | 2012-10-17 | Boehringer Ingelheim International GmbH | Bibw 2992 for use in the treatment of triple negative breast cancer |
JP5808818B2 (ja) | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
WO2013052157A1 (en) | 2011-10-06 | 2013-04-11 | Ratiopharm Gmbh | Crystalline forms of afatinib di-maleate |
CN106279126B (zh) | 2013-07-16 | 2019-05-24 | 杭州普晒医药科技有限公司 | 阿法替尼酸加成盐及其晶型、其制备方法及药物组合物 |
WO2016027243A1 (en) | 2014-08-21 | 2016-02-25 | Dr. Reddy’S Laboratories Limited | Novel solid state forms of afatinib dimaleate |
CN104892584B (zh) | 2015-05-27 | 2018-03-23 | 重庆泰濠制药有限公司 | 一种阿法替尼双马来酸盐无定型态及其制备方法、制剂 |
CN104926800A (zh) | 2015-06-26 | 2015-09-23 | 河北神威药业有限公司 | 一种阿法替尼二马来酸盐的结晶形式及其制备方法 |
-
2003
- 2003-10-17 DE DE10349113A patent/DE10349113A1/de not_active Withdrawn
-
2004
- 2004-09-15 US US10/941,116 patent/US20050085495A1/en not_active Abandoned
- 2004-10-12 PL PL12155662.5T patent/PL2508521T5/pl unknown
- 2004-10-12 NZ NZ583049A patent/NZ583049A/en unknown
- 2004-10-12 EA EA200600604A patent/EA016624B1/ru active Protection Beyond IP Right Term
- 2004-10-12 MX MX2011004537A patent/MX338920B/es unknown
- 2004-10-12 DK DK12155662.5T patent/DK2508521T4/da active
- 2004-10-12 AU AU2004281938A patent/AU2004281938B2/en active Active
- 2004-10-12 PL PL04765927T patent/PL1678165T3/pl unknown
- 2004-10-12 BR BR122013033343A patent/BR122013033343B8/pt active IP Right Grant
- 2004-10-12 ME MEP-2008-508A patent/ME00341B/me unknown
- 2004-10-12 UA UAA200810609A patent/UA91401C2/ru unknown
- 2004-10-12 SI SI200432301T patent/SI2508521T2/sl unknown
- 2004-10-12 UA UAA200605327A patent/UA91006C2/ru unknown
- 2004-10-12 RS RS20060260A patent/RS53398B/en unknown
- 2004-10-12 SI SI200432099T patent/SI1678165T1/sl unknown
- 2004-10-12 CN CN2004800305555A patent/CN1867564B/zh active Active
- 2004-10-12 RS YUP-2006/0260A patent/RS20060260A/sr unknown
- 2004-10-12 HR HRP20160246TT patent/HRP20160246T4/hr unknown
- 2004-10-12 JP JP2006534662A patent/JP4594317B2/ja active Active
- 2004-10-12 HU HUE12155662A patent/HUE028254T2/en unknown
- 2004-10-12 PT PT47659271T patent/PT1678165E/pt unknown
- 2004-10-12 SG SG200800279-2A patent/SG139743A1/en unknown
- 2004-10-12 CA CA2759063A patent/CA2759063C/en active Active
- 2004-10-12 CN CNA2008101664841A patent/CN101402631A/zh active Pending
- 2004-10-12 WO PCT/EP2004/011378 patent/WO2005037824A2/de active Application Filing
- 2004-10-12 BR BRPI0415424A patent/BRPI0415424B8/pt active IP Right Grant
- 2004-10-12 EP EP04765927.1A patent/EP1678165B1/de active Active
- 2004-10-12 CA CA2541928A patent/CA2541928C/en active Active
- 2004-10-12 KR KR1020127003787A patent/KR101282812B1/ko active Protection Beyond IP Right Term
- 2004-10-12 DK DK04765927.1T patent/DK1678165T3/da active
- 2004-10-12 EP EP12155662.5A patent/EP2508521B2/de active Active
- 2004-10-12 NZ NZ547154A patent/NZ547154A/en unknown
- 2004-10-12 MX MXPA06004076A patent/MXPA06004076A/es active IP Right Grant
- 2004-10-12 RS RS20130524A patent/RS60563B1/sr unknown
- 2004-10-12 ES ES04765927.1T patent/ES2440466T3/es active Active
- 2004-10-12 KR KR1020067009605A patent/KR101180752B1/ko active Protection Beyond IP Right Term
- 2004-10-12 PT PT121556625T patent/PT2508521E/pt unknown
- 2004-10-12 ES ES12155662T patent/ES2563211T5/es active Active
- 2004-10-14 MY MYPI20044237A patent/MY149921A/en unknown
- 2004-10-14 UY UY28559A patent/UY28559A1/es active IP Right Grant
- 2004-10-14 MY MYPI2010002645A patent/MY155425A/en unknown
- 2004-10-15 AR ARP040103754A patent/AR046118A1/es not_active Application Discontinuation
- 2004-10-15 TW TW093131395A patent/TWI348468B/zh active
- 2004-10-15 PE PE2010000135A patent/PE20100267A1/es not_active Application Discontinuation
- 2004-10-15 TW TW099147116A patent/TWI373470B/zh active
- 2004-10-15 PE PE2004001000A patent/PE20050965A1/es active IP Right Grant
-
2006
- 2006-03-16 ZA ZA200602234A patent/ZA200602234B/en unknown
- 2006-04-11 IL IL174951A patent/IL174951A/en active IP Right Grant
- 2006-04-17 EC EC2006006509A patent/ECSP066509A/es unknown
- 2006-05-15 NO NO20062181A patent/NO333971B1/no unknown
- 2006-07-14 US US11/457,622 patent/US8426586B2/en active Active
-
2007
- 2007-03-19 HK HK07102938.4A patent/HK1095817A1/xx unknown
-
2010
- 2010-06-21 JP JP2010140697A patent/JP5264830B2/ja active Active
-
2011
- 2011-03-16 AU AU2011201171A patent/AU2011201171B2/en active Active
- 2011-11-10 IL IL216249A patent/IL216249A/en active IP Right Grant
-
2013
- 2013-05-10 NO NO20130663A patent/NO335103B1/no unknown
- 2013-12-09 CY CY20131101112T patent/CY1114866T1/el unknown
- 2013-12-20 HR HRP20131214TT patent/HRP20131214T1/hr unknown
-
2015
- 2015-02-04 UY UY0001035979A patent/UY35979A/es active IP Right Grant
-
2016
- 2016-03-11 CY CY20161100212T patent/CY1117279T1/el unknown
Cited By (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100069414A1 (en) * | 1999-06-21 | 2010-03-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US8722694B2 (en) | 1999-06-21 | 2014-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
USRE43431E1 (en) | 2000-12-20 | 2012-05-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
US20110046168A1 (en) * | 2000-12-20 | 2011-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methods of treating diseases using quinazoline derivatives and pharmaceutical compositions containing them |
US20020173509A1 (en) * | 2000-12-20 | 2002-11-21 | Frank Himmelsbach | Quinazoline derivatives and phamaceutical compositions containing them |
US20100010023A1 (en) * | 2000-12-20 | 2010-01-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
US8586608B2 (en) | 2000-12-20 | 2013-11-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
US8431585B2 (en) | 2002-05-11 | 2013-04-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
US20100144639A1 (en) * | 2002-05-11 | 2010-06-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the egfr-mediated signal transduction for the treatment of benign prostatic hyperplasia (bph) / prostatic hypertrophy |
US20110039863A1 (en) * | 2003-04-29 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
US20110136826A1 (en) * | 2003-04-29 | 2011-06-09 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
US20110171289A1 (en) * | 2003-04-29 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
US20080254040A1 (en) * | 2003-04-29 | 2008-10-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
US7846936B2 (en) | 2003-04-29 | 2010-12-07 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
US8426586B2 (en) | 2003-10-17 | 2013-04-23 | Boehringer Ingelheim International Gmbh | Process for preparing amino crotonyl compounds |
KR101180752B1 (ko) | 2003-10-17 | 2012-09-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 아미노 크로토닐 화합물의 제조방법 |
US20070027170A1 (en) * | 2003-10-17 | 2007-02-01 | Rainer Soyka | Process for preparing amino crotonyl compounds |
EP1951686A4 (en) * | 2005-11-08 | 2010-10-20 | Hanmi Pharm Ind Co Ltd | QUINAZOLINE DERIVATIVES AS MULTIPLEX INHIBITORS AND METHOD FOR THE SYNTHESIS OF SAID DERIVATIVES |
US20080318950A1 (en) * | 2005-11-08 | 2008-12-25 | Hanmi Pharm. Co., Ltd | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof |
JP4918097B2 (ja) * | 2005-11-08 | 2012-04-18 | ハンミ ファーム. シーオー., エルティーディー. | 多重阻害剤としてのキナゾリン誘導体及びその製造方法 |
EP1951686A1 (en) * | 2005-11-08 | 2008-08-06 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof |
US8846699B2 (en) | 2005-11-08 | 2014-09-30 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof |
JP2009514947A (ja) * | 2005-11-08 | 2009-04-09 | ハンミ ファーム. シーオー., エルティーディー. | 多重阻害剤としてのキナゾリン誘導体及びその製造方法 |
US8404697B2 (en) | 2005-11-11 | 2013-03-26 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
US9539258B2 (en) | 2005-11-11 | 2017-01-10 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
US20090306044A1 (en) * | 2005-11-11 | 2009-12-10 | Flavio Solca | Quinazoline derivatives for the treatment of cancer diseases |
US9089571B2 (en) | 2005-11-11 | 2015-07-28 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
US20090306101A1 (en) * | 2005-11-11 | 2009-12-10 | Flavio Solca | Combination treatment of cancer comprising egfr/her2 inhibitors |
US20090306378A1 (en) * | 2006-01-26 | 2009-12-10 | Juergen Schroeder | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
US8067593B2 (en) | 2006-01-26 | 2011-11-29 | Boehringer Ingelheim International Gmbh | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
US20110207929A1 (en) * | 2006-01-26 | 2011-08-25 | Boehringer Ingelheim International Gmbh | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
US20110207932A1 (en) * | 2006-01-26 | 2011-08-25 | Boehringer Ingelheim International Gmbh | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
US8188274B2 (en) | 2006-01-26 | 2012-05-29 | Boehringer Ingelheim International Gmbh | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
US7960546B2 (en) | 2006-01-26 | 2011-06-14 | Boehringer Ingelheim International Gmbh | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
US8877764B2 (en) | 2006-09-18 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring EGFR mutations |
US20090318480A1 (en) * | 2006-09-18 | 2009-12-24 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring egfr mutations |
US8545884B2 (en) | 2008-06-06 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Solid pharmaceutical formulations comprising BIBW 2992 |
US20110142929A1 (en) * | 2008-06-06 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Solid pharmaceutical formulations comprising bibw 2992 |
WO2010104406A1 (en) | 2009-03-11 | 2010-09-16 | Auckland Uniservices Limited | Prodrug forms of kinase inhibitors and their use in therapy |
EP3031807A1 (en) | 2009-03-11 | 2016-06-15 | Auckland UniServices Limited | Prodrug forms of kinase inhibitors and their use in therapy |
US10004743B2 (en) | 2009-07-06 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
US9545381B2 (en) | 2009-07-06 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
WO2011003853A3 (en) * | 2009-07-06 | 2012-01-19 | Boehringer Ingelheim International Gmbh | Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
EP2451445B1 (en) | 2009-07-06 | 2019-04-03 | Boehringer Ingelheim International GmbH | Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
WO2011003853A2 (en) | 2009-07-06 | 2011-01-13 | Boehringer Ingelheim International Gmbh | Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
US20120107304A1 (en) * | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
WO2013052157A1 (en) | 2011-10-06 | 2013-04-11 | Ratiopharm Gmbh | Crystalline forms of afatinib di-maleate |
US9309228B2 (en) | 2012-07-19 | 2016-04-12 | Boehringer Ingelheim International Gmbh | Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as a medicament and the preparation thereof |
US9725439B2 (en) | 2013-09-28 | 2017-08-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinazoline derivative and preparation method therefor |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
US20160122329A1 (en) * | 2014-01-02 | 2016-05-05 | IVAX International GmbH | Crystalline forms of afatinib di-maleate |
US9630952B2 (en) * | 2014-01-02 | 2017-04-25 | IVAX International GmbH | Crystalline forms of afatinib di-maleate |
WO2016051380A1 (en) * | 2014-10-01 | 2016-04-07 | Sun Pharmaceutical Industries Limited | Crystalline form of afatinib dimaleate |
US10011591B2 (en) * | 2014-10-01 | 2018-07-03 | Sun Pharmaceutical Industries Limited | Crystalline form of afatinib dimaleate |
US20170240533A1 (en) * | 2014-10-01 | 2017-08-24 | Sun Pharmaceutical Industries Limited | Crystalline form of afatinib dimaleate |
US9708301B2 (en) * | 2015-01-15 | 2017-07-18 | Hangzhou Pushai Pharmaceutical Technology | Crystalline forms of afatinib monomaleate, preparation methods and pharmaceutical compositions thereof |
US20160207907A1 (en) * | 2015-01-15 | 2016-07-21 | Hangzhou Pushai Pharmaceutical Technology Co., Ltd. | Crystalline Forms of Afatinib Monomaleate, Preparation Methods and Pharmaceutical Compositions Thereof |
US10231973B2 (en) | 2015-03-20 | 2019-03-19 | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. | Salts of quinazoline derivative and method for preparing the same |
CN107980041A (zh) * | 2015-06-12 | 2018-05-01 | 费森尤斯卡比肿瘤学有限公司 | 阿法替尼游离碱及其马来酸氢盐的多晶型形式 |
WO2016199076A3 (en) * | 2015-06-12 | 2017-03-09 | Fresenius Kabi Oncology Ltd. | Polymorphic forms of afatinib free base and afatinib dimaleate |
AU2016276426B2 (en) * | 2015-06-12 | 2019-12-05 | Fresenius Kabi Oncology Ltd. | Polymorphic forms of Afatinib free base and Afatinib dimaleate |
US10800763B2 (en) | 2015-06-12 | 2020-10-13 | Fresenius Kabi Oncology Ltd. | Polymorphic forms of Afatinib free base and Afatinib dimaleate |
US11390612B2 (en) | 2015-06-12 | 2022-07-19 | Fresenius Kabi Oncology Ltd. | Polymorphic forms of Afatinib free base and Afatinib dimaleate |
US10525059B2 (en) | 2015-08-21 | 2020-01-07 | Fresenius Kabi Oncology, Ltd. | Pharmaceutical compositions comprising Afatinib |
US11883403B2 (en) | 2015-08-21 | 2024-01-30 | Fresenius Kabi Oncology Ltd. | Pharmaceutical compositions comprising Afatinib |
US11446302B2 (en) | 2016-11-17 | 2022-09-20 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations |
US11136314B2 (en) | 2017-04-06 | 2021-10-05 | Johnson Matthey Public Limited Company | Forms of afatinib dimaleate |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050085495A1 (en) | Process for preparing amino crotonyl compounds | |
US20150232457A1 (en) | Crystalline forms of afatinib di-maleate | |
US11739057B2 (en) | Polymorphic forms of Belinostat and processes for preparation thereof | |
AU2007309558B2 (en) | Crystal modifications -3- (1H-indol-3-yl) -4- [2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -pyrrole-2, 5-dione | |
JPH04198180A (ja) | ベンジルフタラゾン誘導体の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SOYKA, RAINER;RALL, WERNER;SCHNAUBELT, JUERGEN;AND OTHERS;REEL/FRAME:015429/0034;SIGNING DATES FROM 20041111 TO 20041115 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |